Clinical Trial DRUG CTKI258AUS26
- Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 2 - Dovitinib for Patients with Tumor Pathway Activations Inhibited by Dovitinib Including Tumors with Mutations or Translocations of FGFR, PDGFR, VEGF, CKIT, FLT3, CSFR1, TRK and RET
- Principal Investigator
- Young Chae
- Status: COMPLETED
- Study Type: Therapeutic, Treatment
- Protocol No:.DRUG CTKI258AUS26
- Researchers want to know if dovitinib (TKI258) is safe and has beneficial effects in people who have different tumor types (cancer) and/or blood malignancies whose disease progressed after standard treatment.
- Dovitinib (TKI258) is a drug that is being developed for the potential treatment of different tumor types (cancer), and/or blood malignancies. Dovitinib (TKI258) is an inhibitor of Receptor tyrosine kinases (RTKs): it blocks the activity of three RTKs (VEGF, FGF and PDGF) involved in tumor cell growth. So far, at least 1158 people with different types of tumors have received dovitinib (TKI258), either alone or in combination with another anti-cancer drug.
Some of the eligibility criteria include:
- Participants must be at least 18 years of age.
- Participants must have a confirmed diagnosis of a select solid tumor (except for urothelial tumors, hepatocellular carcinoma, endometrial carcinoma, metastatic breast cancer, squamous non-small cell lung cancer, and renal cell carcinoma) or hematologic malignancy (except for certain types of acute myeloid leukemia and multiple myeloma).
- Participants must need treatment because their cancer is getting worse.
- Participants must have a tumor with a mutation in FGFR 1-3, PDGFRa or PDGFRß, VEGFR1-2 (KDR), FLT3, cKIT, RET, TrkA (NTRK1), or CSF-1R. This is determined by genetic testing.
- Description of Treatment
- In this study, a complete dosing cycle is 28 days. In each cycle, participants will take dovitinib (TKI258) once a day, at approximately the same time every day for 5 days in a row (starting at Day 1 of Cycle 1). After taking the 5 days, participants will have two days “off” when no study drug capsules and/or tablets are taken. This dosing scheduled is called “5 days on/2 days off”. Participants may continue to receive study drug unless they and/or the study doctor decide to stop study drug dosing.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
- Breast: Female
- Endocrine: Thyroid
- Endocrine: Other endocrine system
- Gastrointestinal: Anus
- Gastrointestinal: Colon
- Gastrointestinal: Esophagus
- Gastrointestinal: Stomach
- Gastrointestinal: Liver
- Gastrointestinal: Pancreas
- Gastrointestinal: Small intestine
- Gastrointestinal: Other digestive organ
- Genitourinary: Prostate
- Genitourinary: Other male genital
- Hematology: Other hemapoietic
- Ill-defined sites
- Leukemia: Lymphoid leukemia
- Leukemia: Myeloid leukemia
- Leukemia: Monocytic leukemia
- Leukemia: Leukemia, other
- Lymphoma: Hodgkin's Disease
- Lymphoma: Mycosis Fungoides
- Lymphoma: Non-Hodgkin's Lymphoma
- Skin: Melanoma
- Skin: Kaposi's Sarcoma
- Skin: Other skin
- Soft Tissue
- Unknown, other
- Bones and joints
- Eye and orbit
- Gastrointestinal: Rectum
- Gynecological: Cervix
- Gynecological: Ovarian
- Gynecological: Other female genital
- Head and neck: Buccal cavity/pharynx
- Head and neck: Esophagus
- Head and neck: Larynx
- Head and neck: Thyroid
Other Clinical Trials by Young Chae
- A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
- A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer
- SHERLOC: A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- A Multicenter, Histology-Independent Study of the Fibroblast Growth Factor Receptor (FGFR) Inhibitor Lenvatinib (E7080) in Patients with Advanced Cancer and Aberrations in FGF/FGFR Signaling
last updated: 28-Aug-16 12:08 AM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.